In a filing, Viking Therapeutics Inc revealed its Director Rouan Sarah Kathryn acquired Company’s shares for reported $29943.0 on Mar 31 ’25. In the deal valued at $24.15 per share,1,240 shares were bought. As a result of this transaction, Rouan Sarah Kathryn now holds 1,240 shares worth roughly $28048.800000000003.
Then, Lian Brian sold 194,490 shares, generating $8,313,601 in total proceeds. Upon selling the shares at $42.75, the President & CEO now owns 2,366,570 shares.
Before that, Mancini Marianna sold 54,215 shares. Viking Therapeutics Inc shares valued at $2,317,599 were divested by the Chief Operating Officer at a price of $42.75 per share. As a result of the transaction, Mancini Marianna now holds 374,134 shares, worth roughly $8.46 million.
Scotiabank initiated its Viking Therapeutics Inc [VKTX] rating to a Sector outperform in a research note published on February 13, 2025; the price target was $102. A number of analysts have revised their coverage, including Citigroup’s analysts, who began to cover the stock in early February with a ‘”a Neutral”‘ rating. Piper Sandler began covering VKTX with “an Overweight” recommendation on December 02, 2024. B. Riley Securities started covering the stock on November 22, 2024. It rated VKTX as “a Buy”.
Price Performance Review of VKTX
On Friday, Viking Therapeutics Inc [NASDAQ:VKTX] saw its stock fall -6.61% to $22.62. Over the last five days, the stock has lost -11.81%. Viking Therapeutics Inc shares have fallen nearly -43.79% since the year began. Nevertheless, the stocks have fallen -71.16% over the past one year. While a 52-week high of $81.86 was reached on 01/06/25, a 52-week low of $23.27 was recorded on 04/04/25. SMA at 50 days reached $29.40, while 200 days put it at $49.01.
Levels Of Support And Resistance For VKTX Stock
The 24-hour chart illustrates a support level at 21.55, which if violated will result in even more drops to 20.47. On the upside, there is a resistance level at 23.68. A further resistance level may holdings at 24.73. The Relative Strength Index (RSI) on the 14-day chart is 33.55, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.45, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 88.18%. Stochastics %K at 17.79% indicates the stock is a buying.
How much short interest is there in Viking Therapeutics Inc?
A steep rise in short interest was recorded in Viking Therapeutics Inc stocks on 2025-03-14, dropping by -0.89 million shares to a total of 24.21 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 25.11 million shares. There was a decline of -3.69%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 04, 2024 when H.C. Wainwright resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $102.
